Tanapoxvirus: From discovery towards oncolytic immunovirotherapy

Area of Science:

• Virology
• Oncology
• Gene Therapy

Background:

• Standard cancer therapies like chemotherapy and radiotherapy have limitations, including toxicity and ineffectiveness against metastatic cancers.
• Oncolytic viruses (OVs) represent a promising alternative therapeutic strategy for various human cancers.
• Tanapoxvirus (TANV), a poxvirus, is being developed as an OV due to its favorable safety and efficacy characteristics.

Purpose of the Study:

• To provide a comprehensive review of Tanapoxvirus (TANV) as an oncolytic virus (OV) candidate.
• To summarize the discovery, molecular characterization, and preclinical development of TANV for cancer therapy.
• To highlight TANV's potential in treating a wide range of human cancers.

Main Methods:

• Review of existing literature on Tanapoxvirus (TANV) discovery, characterization, and preclinical studies.
• Analysis of TANV's molecular and clinical data regarding its safety and efficacy as an oncolytic virus.
• Evaluation of TANV's replication capabilities in human cancer cells and its tumor regression effects in animal models.

Main Results:

• Tanapoxvirus (TANV) exhibits desirable safety features, including mild self-limiting disease in humans and no human-to-human transmission.
• TANV demonstrates effective replication in various human cancer cell lines in vitro and has shown tumor regression in preclinical models.
• TANV's large genome and slower replication rate compared to vaccinia virus contribute to its potential as a safer OV.

Conclusions:

• Tanapoxvirus (TANV) is a well-characterized poxvirus with significant potential as an oncolytic virus for treating multiple human cancers.
• TANV's unique safety and efficacy profile supports its continued development as a novel cancer therapeutic.
• Further clinical studies are warranted to establish TANV's role in the therapeutic landscape for metastatic and other cancers.